Drug compounds continue to show promise in activating Ube3a in Angelman syndrome mouse model
Drug compounds continue to show promise in activating Ube3a in Angelman syndrome mouse model
Dr. Benjamin Philpot’s lab at the University of North Carolina Chapel Hill continues to make headway in identifying drug compounds that may lead to a viable treatment for Angelman syndrome. As announced on Monday, April 29th from the Simons Foundation Autism Research Initiative, this research has found 30 drug compounds that activate the paternal copy of Ube3a in an Angelman syndrome mouse model. This research is ongoing, and was launched by an ASF-funded research grant to Philpot’s lab in 2011 that resulted in the initial research breakthrough that topoisomerase inhibitors may provide a viable treatment for Angelman syndrome.
You may read more about this latest research update on SFARI’s website by clicking here. You may also read more about the 2011 research breakthrough by clicking here.